This report summarizes the clinical course of 17 patients with non-Hodgkin’s lymphomas who were treated with high dose intermittent intravenous cyclophosphamide between 1966 and 1968. Diagnostic biopsies have been reclassified according to the Rappaport classification. Five patients were found to have diffuse lymphomas, none of whom experienced complete remission or prolonged survival. Twelve patients had nodular lymphomas, five of whom achieved complete remission lasting from 22 to 113 + months (mean 59 + months). Two patients survived 78 and 113 + months, respectively, with no sign of recurrence. High dose cyclophosphamide alone may provide long term control of some patients with nodular lymphomas.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.